GYRE — Gyre Therapeutics, Inc.

Catalyst Biosciences Q3 2021 Earnings Call Summary

1. Key Financial Results and Metrics:

• Cash position as of September 30, 2021, was reported at $64.5 million.
• The company anticipates a 40% reduction in cash burn, decreasing from approximately $20 million per quarter to around $13 million.

2. Strategic Updates and Business Highlights:

• Catalyst Biosciences announced a strategic pivot, halting the clinical development of MarzAA to focus on its complement programs and protease medicines platform.
• The decision to discontinue MarzAA was influenced by slow enrollment in clinical trials and increased competition for study subjects.
• The company plans to report existing data from the MarzAA trials, which indicate successful treatment of bleeds without adverse events.
• Catalyst is exploring opportunities to license or sell the MarzAA and DalcA portfolio.
• The complement portfolio includes candidates CB 4332 (a complement factor I therapy) and CB 2782-PEG (a C3 degrader licensed to Biogen), with plans to submit an IND for CB 4332 in 2022.

3. Forward Guidance and Outlook:

• The company aims to initiate first-in-human trials for CB 4332 in 2022.
• Catalyst expects to nominate its next development candidate from its protease platform in 2022.
• The complement market is viewed as a significant growth opportunity, with potential applications in nephrology, inflammation, and ophthalmology.

4. Bad News, Challenges, or Points of Concern:

• The decision to halt MarzAA development reflects challenges in clinical trial enrollment and the financial viability of continuing the program without a partner.
• The timeline for completing the MarzAA trials has been pushed to late 2023, which is viewed as a significant hurdle.
• The competitive landscape for hemophilia therapies is intensifying, posing risks to future development and market entry.

5. Notable Q&A Insights:

• Management confirmed that the slow enrollment in the MarzAA trials was a primary driver for the strategic shift, with logistical challenges exacerbated by the pandemic.
• There is ongoing outreach to potential partners for MarzAA, although no specific discussions were disclosed.
• The company expressed confidence in the immunogenicity profile of CB 4332, having conducted thorough risk assessments.
• The complement factor I deficiency is considered an ultra-orphan indication, with efforts underway to identify and enroll patients for upcoming trials.

In summary, Catalyst Biosciences is refocusing its strategy on complement therapies, moving away from MarzAA due to enrollment and competitive challenges. The company maintains a positive outlook on its complement pipeline while managing financial resources more conservatively.